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ABSTRACT 
Despite improvements in operating technique and post-operative management, many patients 
undergoing liver transplantation still suffer post-operative complications, which may lead to 
graft loss or patient death. Patients are monitored closely post-operatively using blood 
chemistry, diagnostic imaging and liver biopsies to detect these complications including 
rejection and arterial- and portal vein thrombosis. However, signs and symptoms of these 
complications may be subtle and nonspecific leading to a delay in diagnosis and intervention. 
Microdialysis is a sampling technique, which allows for continuous monitoring of 
metabolites in the tissue in which it is placed. The aim of this thesis was to study intaorgan 
metabolism using microdialysis early after liver transplantation as well as in tissue subject to 
compression, to identify metabolic patterns signaling distress so that major complications 
may be detected before they are reflected in clinical exam or blood chemistry.  
In paper I the impact of compression and possible hypoperfusion on tissue metabolism was 
studied using microdialysis in kidney during pneumoperitoneum in a pig model. A significant 
increase in glycerol in the renal medulla after desufflation was shown.  
In paper II a pig liver transplantation model was used to study the impact of short and long 
cold ischemia time on the restoration of glucose metabolism. An increase in intrahepatic 
glucose following portal reperfusion was seen in both groups and was significantly higher in 
the group with long cold ischemia. An increase in intrahepatic lactate/pyruvate ratio was also 
seen in both groups but was significantly higher and prolonged in the group with long cold 
ischemia time.  
In paper III a clinical study showed no correlation between episodes of increased 
intrahepatic lactate/pyruvate  and development of ischemic complications after liver 
transplantation.  
In paper IV an increase in the lactate/pyruvate ratio in the liver during the initial 12 hours 
post-transplant was found to be correlated to development of post-transplant rejection in a 
clinical study.  
Paper V investigated whether a microdialysis catheter placed in the middle hepatic vein is 
comparable to intrahepatic microdialysis for monitoring liver metabolism during clamping of 
the hepatic artery using a pig model. It was not.  
In conclusion, the microdialysis technique has proven to be a promising tool for continuous 
monitoring of tissue metabolism and pharmacological studies. However, despite encouraging 
results from animal experiments and a wide range of clinical studies over the past two 
decades, microdialysis has not gained a foothold in standard clinical practice. It seems that 
microdialysis is useful for the detection of primary metabolic changes. However, a better 
understanding of the recovery of metabolic processes after the ischemia reperfusion injury 
occurring during the transplantation process is needed to use microdialysis for monitoring of 
secondary events following liver transplantation.   
POPULÄRVETENSKAPLIG SAMMANFATTNING 
Trots förbättringar av operationsteknik och postoperativ vård drabbas många patienter som 
genomgår levertransplantation av komplikationer som kan leda till döden eller förlust av det 
transplanterade organet. Av denna anledning följs levertransplanterade patienter noga 
postoperativt med blodprover, bilddiagnostik och leverbiopsier. Syftet är att upptäcka 
komplikationer såsom avstötning och artär- och portaventrombos (blodpropp i leverns 
blodkärl) så att behandling kan sättas in i ett tidigt skede. Symtombilden för dessa 
komplikationer varierar och är ibland mycket subtil vilket kan leda till sen diagnos och 
intervention. Mikrodialys är en diagnostisk metod för att mäta olika ämnen i kroppens 
kolhydrat- och fettomsättning. Vanligtvis mäts metaboliterna glukos, laktat, pyruvat och 
glycerol. Tidigare studier har visat att laktat/pyruvat-kvoten (L/Pr) stiger vid syrebrist i 
vävnaden. Genom att mäta dessa ämnen i den transplanterade levern får man en detaljerad 
och kontinuerlig övervakning av organet. Målet för de studier som ligger till grund för denna 
avhandling var att med hjälp av mikrodialys upptäcka komplikationer innan de ger kliniska 
symtom och påverkade blodprover.  
I vår första studie undersöktes hur ökat tryck i bukhålan påverkar njurvävnad i samband med 
njurdonation. För att studera detta användes en djurförsöksmodell med gris. Resultaten visar 
ökade nivåer av glycerol i njurmärgen vilket tyder på vävnadsskada. 
I samband med levertransplantation utsätts levern för en period med cirkulationsuppehåll då 
den kyls ned för att begränsa cellskada, så kallad kall ischemitid. I vår andra studie 
undersökte vi hur lång respektive kort kall ischemitid påverkar kolhydrat- och 
fettmetabolismen i levern genom att använda en djurförsöksmodell med gris. Vi fann att L/Pr 
steg efter att levern återfått cirkulation och stegringen var betydligt högre i gruppen med lång 
kall ischemitid. Resultaten tyder på att de mekanismer som styr kolhydratomsättningen i 
levern påverkas under ischemitiden och att det tar längre tid för dessa system att återhämta 
sig vid lång kall ischemitid.  
Vår tredje studie är en klinisk studie i vilken patienter som genomgick levertransplantation 
övervakades med mikrodialys postoperativt. Vi fann inget samband mellan ökad L/Pr och 
komplikationer kopplade till syrebrist. Resultaten tyder på att L/Pr inte kan användas för att 
upptäcka dessa komplikationer hos patienter. 
Vår fjärde studie är en klinisk studie i vilken patienter som genomgick levertransplantation 
övervakades med mikrodialys postoperativt. Vi fann att patienter som senare utvecklade 
avstötning hade högre L/Pr under de första 12 timmarna efter levertransplantation.  
I vår femte studie undersöker vi om mikrodialys som placeras i levervenen (intravenöst) kan 
ersätta mikrodialys placerad i leverparenkymet för övervakning av kolhydrat- och 
lipidmetabolism i lever som utsätts för syrebrist. Resultaten visar att intravenös mikrodialys 
inte kan ersätta mikrodialys i levern. 
  
Sammanfattningsvis har mikrodialys varit ett lovande verktyg för att övervaka metabolism i 
vävnader och i farmakologiska studier. Trots initialt positiva resultat från experimentella och 
kliniska studier har tekniken inte etablerats som klinisk standard för övervakning av patienter. 
Mikrodialys är användbart för att följa primära metabola förändringar i vävnaden. För att 
kunna använda mikrodialys för att upptäcka komplikationer efter levertransplantation behövs 
dock mer kunskap om hur metabola processer återhämtar sig efter transplantationsprocessen. 
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1 INTRODUCTION 
1.1.1 Background of the study 
Each year approximately 30.000 liver transplants are performed world-wide (1). For patients 
suffering from terminal liver disease, receiving a liver transplantation is often a lifesaving 
treatment (2-4). Improvements in operating technique and post-operative management have 
dramatically increased the safety of the procedure since the first successful liver 
transplantation performed by Thomas Starzl in 1967 (2, 5, 6). Yet many patients still suffer 
post-operative complications which may lead to graft loss or death (4, 7, 8). Patients are 
monitored closely post-operatively using blood chemistry, diagnostic imaging and liver 
biopsies to detect these life-threatening complications including rejection and arterial- and 
portal vein thrombosis. However, signs and symptoms of these complications in early stage 
may be subtle and nonspecific leading to a delay in diagnosis and intervention and ultimately 
worse outcome (9, 10). As organ shortage has pushed toward the usage of extended criteria 
donors (previously known as marginal donors), new methods of assessing and monitoring 
liver grafts intra- and post operatively would be helpful for prediction of graft function and 
early detection of complications (11-14).  
 
1.1.2 Outcome after liver transplantation 
Factors, which impact outcome after liver transplantation depend on recipient-, donor- and 
peri-operative parameters (3, 13). Recipient characteristics that influence outcome include 
urgent indication for liver transplantation, age, presence of infection and cancer. End-stage 
liver disease is assessed by use of a scoring system; Model for End-Stage Liver Disease 
(MELD) which is used for prioritizing patients for receipt of a liver transplant (15). Donor 
characteristics such as advanced age, degree of steatosis of the liver, length of hospital stay 
and infection can have a negative impact on the posttransplant outcome (3). Such donors with 
high risk of post-transplant complications are called extended criteria donors (13, 14). As for 
perioperative factors, the organ preservation and length of cold and rewarming ischemia time 
as well as the experience level of the transplant centre also influence outcomes after liver 
transplantation (3). An overview of the liver transplantation procedure is outlined in Figure 1. 
Post-operative complications may follow any surgical procedure. In this chapter some major 
complications occurring in the early post-operative period after liver transplantation are 
discussed. 
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Figure 1. Overview of liver transplantation procedure including procurement, storage and 
transplantation 
 
1.2 VASCULAR COMPLICATIONS 
1.2.1 Hepatic artery thrombosis 
Following orthotopic liver transplantation circulation to the liver graft is re-established by 
anastomosis of the supra- and infra-hepatic inferior vena cava, portal vein and the hepatic 
artery (16) (Figure 2).  
 
Figure 2. Anatomy of conventional orthotopic liver transplantation in anterior-posterior view 
and lateral view.  
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Nowadays, a modification of this classical technique is used with vena cava preservation on 
the recipient site (piggy-back technique) (Figure 3) (17).  
 
Figure 3. Classical “piggy-back” technique in anterior-posterior view and lateral view. 
Hepatic artery thrombosis (HAT) is the most common vascular complication and has an 
incidence of 1.6-9% in adults and 5-8% in paediatric patients (7, 18-20). It is also the most 
common complication requiring re-transplantation (7, 21). For this life-threatening 
complication mortality rates range from 11% to 23% (20, 22, 23).  
HAT can occur at any time following liver transplantation. The clinical presentation varies 
and depends on the time interval between transplant, thrombosis and the time of diagnosis 
(20). Symptoms range from fulminant hepatic necrosis with hepatic decompensation, sepsis 
and coagulopathy to less dramatic but progressive symptoms developing because of ischemic 
bile duct injury. The latter may give rise to non-specific symptoms such as fever, increased 
transaminases, cholangitis, and sepsis. HAT is diagnosed using radiological imaging or 
surgical exploration or both. Ultrasonography is used as a screening method in many centres 
during the initial postoperative period and has been shown to have a high sensitivity for HAT 
detection (24). Factors associated with the development of HAT include celiac trunk stenosis, 
technical imperfections of the anastomosis and increased vascular resistance distal to the 
anastomosis due to rejection or ischemia-reperfusion injury (7). 
Depending on the clinical status of the patient HAT is managed differently. Fulminant 
hepatic failure due to HAT requires re-transplantation. In patients where HAT has been 
discovered early and symptoms are less severe graft salvage is attempted by expeditious 
surgical intervention. Following advances in recent years in endovascular intervention, this 
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has become an acceptable alternative treatment option for revascularization of the graft in 
some cases (25-27). Asymptomatic HAT cases are treated conservatively. 
Considering the persistent shortage of organs and the increased risk of poor outcome 
associated with vascular complications, diagnostic improvements allowing for earlier 
detection and treatment of HAT may have profound impact on patient and graft survival. 
1.2.2 Portal vein thrombosis 
Approximately 75% of the blood flow and 50% of the oxygen supply to the liver is delivered 
through the portal vein. Portal vein thrombosis is a rare but severe complication following 
liver transplantation. The incidence is reported at 1-3% in the adult population (28-30). 
Presenting symptoms include liver failure, ascites and gastrointestinal bleeding (7). If 
detected and treated expeditiously radiological invasive intervention and anticoagulative 
therapy may be successful in preventing graft loss. However, re-transplantation rate is 
reported around 20% and long-term survival rates are significantly reduced (7, 23). Portal 
vein thrombosis triggers a compensatory vasodilation of the hepatic artery called the arterial 
buffer response (31). This ensures enough oxygen delivery to the liver to preserve liver 
function. Patients without pre-transplant portal hypertension develop persistent or de novo 
signs of portal hypertension such as hepatopulmonary syndrome, ascites, gastrointestinal 
bleeding and encephalopathy.  
1.3 REJECTION 
Allograft rejection is classified as acute or chronic depending on onset, reversibility and 
histological characteristics. The incidence of acute cellular rejection (ACR) has decreased 
due to improvements in immunosuppressive therapy but still occurs in 15-40% of liver 
transplanted patients with most cases occurring within the first year after transplantation (10, 
32-34). Several risk factors for development of ACR have been identified including but not 
limited to autoimmune aetiology of liver disease prompting liver transplantation, CMV 
infection, male donor to female recipient, higher donor age and long ischemia time (10, 33). 
ACR usually responds well to treatment with steroid boluses or increased basic 
immunosuppressive regimen (10). Isolated events of ACR do not affect long-term outcome in 
terms of patient or graft survival, however repeated insults may predispose to chronic 
rejection (CR) (10, 35, 36). ACR may be asymptomatic or present with malaise, fever or 
abdominal pain. The condition is often suspected following elevation of transaminases, 
alkaline phosphatase, gamma-glutamyl transpeptidase and bilirubin (10). However, neither 
symptoms nor blood chemistry changes are specific for distinguishing ACR from other 
complications after liver transplantation and a liver biopsy continues to be the gold standard 
required for final diagnosis. The severity of ACR is graded using the Rejection Activity Index 
(RAI) which takes into account the degree of portal inflammation, bile duct inflammation 
damage and venous endothelial inflammation (37). 
CR is an immunological reaction to the liver allograft resulting in a progressive destruction of 
bile ducts and cholestatic liver dysfunction without major inflammation (38). The incidence 
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rate of CR is reported at 2-17% in liver transplanted patients (39-41). CR is chronic but can 
present at any time following liver transplantation. While episodes of ACR usually respond 
well to treatment, CR is associated with a significant risk of graft loss and death despite the 
use of high doses of immunosuppression (39).  
Following the introduction of modern immunosuppressive agents the incidence rate of 
allograft rejection has dropped markedly and the general outcome after liver transplantation 
has improved substantially (42). However significant morbidity results from side effects of 
continuous immunosuppressive treatment with increased risk of cardiovascular disease, 
nephrotoxicity, infection and a two to four-fold elevated risk of neoplasms (42, 43). In view 
of this, tolerance induction (total withdrawal of immunosuppressive medication after 
transplantation without negative effect on the graft in the form of rejection) has become a 
major goal for the transplant community in recent years. Studies suggest that tolerance may 
be possible to achieve in 20%-70% of liver transplanted patients (44-47). However, a better 
understanding of the underlying mechanisms of tolerance induction is warranted and new 
biochemical- and genetic markers are needed to identify patients who may be candidates for 
weaning protocols (34, 47, 48).  
1.4 ISCHEMIA-REPERFUSION INJURY OF THE LIVER 
Procurement, storage and implantation of the donor liver entails a transient deprivation of 
oxygen followed by restauration of blood circulation and oxygen delivery to the tissue 
resulting in cellular damage called ischemia-reperfusion injury (IRI) (49, 50). After 
harvesting, the liver graft is stored in hypothermic conditions to reduce metabolic activity and 
energy demand during transport, a period referred to as cold ischemia time (CI) (Figure 1). 
During implantation re-warming of the organ inevitably occurs. Before circulation has been 
re-established, the liver graft is thus exposed to a period of warm ischemia (WI) (rewarming 
time). IRI is the result of a continuum of complex inflammatory and immunological 
processes causing structural cell- and tissue damage in different ways during cold and warm 
ischemia time and after reperfusion. The length of ischemia time is strongly correlated to the 
degree of IRI with longer cold ischemia time resulting in more severe injury (51).  
IRI is related to a higher incidence of early graft non-function as well as acute and chronic 
rejection (49, 52, 53). Also, organs from extended criteria donors as well as organs exposed 
to prolonged ischemia are more susceptible to IRI (50, 52). New diagnostic methods which 
allow for assessing the degree of ischemic injury followed by reperfusion injury could aid in 
identifying patients who are at greater risk of developing allograft rejection. Furthermore, a 
better understanding and prevention of IRI has the potential of significantly expanding the 
donor pool as more organs from extended criteria donors could be considered for 
transplantation. 
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1.5 LIVING DONOR NEPHRECTOMY AND KIDNEY TRANSPLANTATION 
1.5.1 The Kidney 
The kidney has several functions including regulation of fluid balance, electrolytes, blood 
pressure and production of various hormones. The smallest functional unit of the kidney is 
the nephron which produces urine by filtration of fluid from the blood. Filtration occurs from 
a spool of branching capillaries in the glomerulus. The filtrate being passed into Bowman’s 
capsule, flows through different sections of tubules until finally reaching collecting ducts and 
the renal hilus as urine. Morphologically, the kidney is made up of an outer renal cortex and 
the inner renal medulla.  
1.5.2 Renal Transplantation 
Renal transplantation is the preferred treatment for patients with end-stage renal disease 
(ESRD) (54-57). Since the first long-term successful kidney transplant performed in 1953 
between monozygotic twins, the safety and outcome of the procedure have improved 
radically. Living donor renal transplantation has become an increasingly important treatment 
option for ESRD given the growing shortage of donors and superior outcomes for recipients 
(57, 58). Open surgery for donor nephrectomy was previously the first choice for living 
kidney transplantation. However, due to improvements in the laparoscopic technique and the 
associated advantages such as less post-operative pain, shorter hospital stay and better 
cosmesis than the open procedure, laparoscopic donor nephrectomy has become the standard 
of care for living donor renal transplantation (59, 60). By reducing donor morbidity, 
laparoscopic nephrectomy has also lowered the threshold for donation which helps to expand 
the donor pool (58). Laparoscopic donor nephrectomy can be performed through a 
transperitoneal- or retroperitoneal approach. The transperitoneal approach is associated with a 
higher risk of bowel injury and late onset bowel obstruction than the retroperitoneal approach 
(61, 62). Recently, robotic-assisted techniques for living donor nephrectomy have also been 
introduced in several centres (63, 64).  
Prior to the study presented in Paper I, laparoscopic living donor transplantation was shown 
to be associated with higher creatinine levels and delayed initial graft function during the first 
week after transplantation, in comparison to open living donor nephrectomy (61, 65, 66). 
Presumably this graft dysfunction can be attributed to handling of the graft, longer warm 
ischemia time and pneumoperitoneum potentially causing renal ischemia. However, the effect 
of the procurement procedure on graft metabolism is not fully known. 
1.6 METABOLOMICS 
Metabolomics is the study of small molecule metabolites (<1.5 kDa) in tissues, cells and 
biofluids. Metabolites are products or substrates of metabolic pathways central to all living 
cells. Measuring them in the tissue of interest provides a metabolic profile reflecting 
biochemical activity on a cellular level (67). The field of metabolomics offers new ways of 
identifying biomarkers as well as describing and understanding biological phenotypes. Mass 
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spectrometry (MS) and Nuclear Magnetic Resonance (NMR) spectroscopy are the techniques 
most commonly used for analysing the 30,000 human metabolites which have been identified 
so far (68). Glucose, lactate and pyruvate are biomarkers commonly used to describe the 
balance between aerobic and anaerobic metabolism (69, 70) (Figure 4).  
 
Figure 4. Aerobic and anaerobic pathways of cellular respiration 
While MS and NMR describe intracellular metabolism, these techniques do not allow for 
continuous monitoring over longer time. To better follow the biochemical status of the cells 
over time microdialysis has been introduced. It offers the potential of direct monitoring of the 
metabolism in the tissue in which the microdialysis catheter is placed. Microdialysis is a 
sampling technique which mimics the passive function of a capillary blood vessel and allows 
for continuous monitoring of metabolites with short time intervals (a few minutes) over up to 
two-three weeks.  
Glucose is the main source of energy in human cells. It is metabolised through the process of 
glycolysis to yield energy in the form of ATP as well as intermediates essential in other 
metabolic pathways. Upon entering the cell through a glucose transporter, glucose is 
phosphorylated and becomes glucose-6-phosphate. This traps glucose within the cell and 
allows for further metabolization through the glycolysis pathway. Glucose can also be stored 
in the form of glycogen in skeletal muscle and the liver. When glycogen stores are depleted 
glucose is synthesised from precursors such as glycerol, pyruvate and lactate by the process 
of gluconeogenesis (71).  
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In the presence of oxygen, the end product of glycolysis is two pyruvate molecules. Pyruvate 
is converted to acetyl CoA, -the main substrate of the citric acid cycle. The citric acid cycle is 
the metabolic pathway by which energy is produced from oxidation of NADH in the 
mitochondria of the cell. The net production of energy from one glucose molecule is 36 ATP. 
In the absence of oxygen pyruvate is reduced to lactate. This upholds glycolysis and ATP 
production in the cell albeit with a significantly lower energy yield of 2 ATP and an 
accumulation of lactate causing acidosis (Figure 4).  
Although an increase in serum lactate levels is often seen in late stages of extensive tissue 
ischemia, lactate has proven to be a poor early marker for tissue ischemia (72, 73). This may 
be explained by clearance of lactate from serum by the liver causing a delay in lactate 
increase in the serum. Also, lactate increase can be seen in non-ischemic conditions as a 
result of hypermetabolism (73). Instead the lactate/pyruvate ratio (L/Pr) is widely used as 
an indicator of ischemia (74-77). During ischemia lactate accumulates and pyruvate is 
consumed as glycolysis increases, resulting in an increase in the L/Pr.  
Measurement of tissue levels of glucose and its derivatives has been described in abdominal 
surgery, plastic surgery and is a well-established laboratory tool in neurosurgery for detection 
of ischemic complications in the tissue of interest (74, 78-80).  
Glycerol is a three-carbon molecule central to lipid metabolism in the human body. It 
constitutes the backbone of glycerophospholipids which make up internal and external 
cellular membranes. Glycerol is also found bound to fatty acids in triacylglycerol in adipose 
cells. When energy requirements increase during stress or starvation, glycerol is released 
from fatty acids through lipolysis. The free fatty acids are either used in the energy 
production within the cell or released to the blood and carried to other tissues. As adipose 
cells lack the ability to metabolize glycerol it is transported to the liver where it is converted 
to dihydroxyacetone phosphate which can enter glycolysis or gluconeogenesis (71, 81). 
During apoptosis or cell injury, phospholipases break down cellular membranes, releasing 
glycerol and fatty acids to the extra cellular space. Increase in glycerol may thus reflect 
increased lipolysis or indicate disintegration of cellular membranes (82). It has been 
considered as a marker for tissue damage and cell death in neurosurgical studies (83).   
1.7  LIVER METABOLISM DURING TRANSPLANTATION 
During the transplantation process the liver is deprived of oxygen and suffers from periods of 
cold preservation and warm ischemia before reperfusion. The lack of oxygen halts aerobic 
energy production and the degradation of glucose through the citric acid cycle. However, 
several intra-cellular pathways requiring energy are still in operation. In order to uphold 
energy production pyruvate is converted to lactate. Also, the balance between glycolysis and 
gluconeogenesis shifts toward gluconeogenesis during warm and cold ischemia (84). While 
short periods of oxygen deprivation can be compensated for in this way, longer ischemic 
insults result in deterioration of essential metabolic pathways such as mitochondrial oxidative 
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phosphorylation (85, 86). Ultimately this leads to hepatocyte dysfunction and poor transplant 
outcome (84, 87).  
The liver plays an essential role in the regulation of carbohydrate-, lipid- and protein 
metabolism (Figure 5). In the well-fed state the liver stores glucose in the form of glycogen. 
When blood glucose levels drop, glycogen is broken down to glucose and released into the 
bloodstream to maintain stable blood glucose levels. Some of the metabolic pathways and 
enzymes which regulate these functions are unique to hepatocytes and upholding them 
throughout the procurement, storage and reimplantation process is paramount for graft and 
patient survival (84, 87).   
 
Figure 5. Summary of carbohydrate-, lipid- and protein-metabolism in the liver. 
By studying intrahepatic metabolism using microdialysis during and early after liver 
transplantation as well as metabolism in tissue subject to compression we hope to identify 
metabolic patterns signalling distress so that major complications may be detected before 
they are reflected in clinical exam or blood chemistry. 
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2 AIMS 
 
General  
The thesis aims to evaluate monitoring of glucose, lactate, pyruvate and glycerol in the 
kidney and in the liver using microdialysis, for detection of major complications such as 
ischemia and rejection early after liver transplantation 
 
Aims of the individual studies 
 
Study I 
To study the impact of compression and possible hypoperfusion on tissue metabolism using 
microdialysis in kidney during pneumoperitoneum in a large animal model. 
 
Study II 
To study the impact of short and long CI time on the restoration of glucose metabolism in the 
liver using a pig experimental model of liver transplantation. 
 
Study III 
To evaluate the intrahepatic L/Pr as a clinical marker for ischemic complications such as 
hepatic artery thrombosis by using microdialysis early after human transplantation. 
 
Study IV 
To evaluate intrahepatic glucose, lactate, pyruvate and glycerol as potential markers for 
rejection early after human liver transplantation using microdialysis. 
 
Study V 
To study if results from a microdialysis catheter placed in the middle hepatic vein is 
comparable with results from intrahepatic microdialysis during monitoring of liver 
metabolism during arterial ischemia a pig model. 
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3 METHODS USED IN THE THESIS 
 
3.1.1 Microdialysis: Principles and technique 
The notion of analysing samples of interstitial fluid collected by use of dialysis bags was 
introduced in the 1960’s by Bito et al (49). In 1974 Ungerstedt and Pycock made substantial 
improvements to the concept and catheter design which has given the technique its current 
form (50).  
Microdialysis is a sampling technique for continuous measuring of small-molecular-weight 
substances in the interstitial space of living tissue. A double lumen catheter is placed in the 
tissue of interest and perfused with a physiological fluid. The catheter, or microdialysis probe, 
is fitted with a semipermeable membrane at the tip over which small molecules can cross by 
passive diffusion (Figure 6).  
 
Figure 6. Illustration of semipermeable membrane at the tip of the microdialysis probe. With 
courtesy of M Dialysis AB. 
The perfusate is pumped through the inner lumen of the catheter, to the semipermeable 
membrane where it equilibrates with the extra-cellular fluid. The perfusate is then collected 
through the outer lumen, in vials which are analysed at the bedside (Figure 7).  
  
 
 
 
 
 
 
Figure 7. Microdialysis catheter, sampling vial and pump. With courtesy of M Dialysis AB. 
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The recovery of the substance to be measured is dependent on the perfusion rate of the liquid 
pumped through catheter, the length and properties of the dialysis membrane and the 
diffusion of the substance through extracellular fluid (70). A high perfusion rate gives less 
time for diffusion over the membrane and thus lower recovery rate. A low perfusion rate 
gives a higher recovery but the collection period may become inappropriately long. A 
perfusion rate of 0.3 l/min is considered to give close to 100% recovery for measurements in 
biological tissue (70, 88). Usually perfusion rates range from 0.3-1.0 l/min. The 
microdialysis probe is available in several different membrane- and shaft lengths and the 
molecular weight cut-off (MWCO) ranges between approximately 6 to 100 kDa. The speed 
by which molecules diffuse through the extracellular tissue will affect the amount of 
substance which will be recovered as well as how quickly any change can be detected (70). 
Also, molecules with molecular weight close to that of the MWCO have a lower recovery 
rate. Analytes with molecular size of one third to one fifth of the MWCO are considered to be 
recovered at a significant rate (89). The catheters used in our studies (CMA 70, with a 60 mm 
shaft, diameter 0.9 mm and a 30 mm membrane, diameter 0.6mm) has a MWCO of 20 kDa. 
The analytes studied are glucose (180 Da), lactate (90 Da), pyruvate (88 Da) and glycerol (92 
Da). As the analytes all have a molecular weight well below one fifth of the MWCO they can 
be expected to diffuse freely across the membrane. Enzymes such as lactate dehydrogenase 
(143 kDa) which might affect the concentration of analytes are too big to pass over the 
membrane wherefore the concentration of analytes in the sampled fluid is considered stable. 
Analytes diffuse more easily through an aqueous solution than in tissue (90). This must also 
be considered when estimating recovery rate. The sampled fluid, collected in vials, is 
analysed bedside using enzyme reaction specific for each analyte, followed by liquid 
chromatography. Samples may also be stored for up to 1 month at -20oC. 
3.1.2 Strengths and limitations of microdialysis 
Microdialysis has proven to be a minimally invasive and easy to use technique for studying 
metabolic changes in various tissues such as brain, muscle, small intestine and adipose tissue 
(78, 91-93). The microdialysis catheter brings little or no discomfort to the patient and is 
easily removed at the end of monitoring. The technique provides an opportunity to monitor 
metabolic trends in real time with approximately 20-minutes delay owing to sampling. 
However, there are potential limitations to the microdialysis technique. Measurements 
obtained show analyte concentrations directly surrounding the catheter and may not be 
representative of the entire organ. Also, the introduction of the catheter inevitably causes 
some degree of damage in the tissue leading to inflammatory reactions which could influence 
test results (69). As scar tissue forms around the catheter the ability for metabolites to diffuse 
across the membrane changes which may affect recovery rate over time (94). When studying 
glucose and it’s metabolites the fact that concentrations may also be influenced by nutrition, 
intravenous infusions, medication and anaesthesia must be considered when interpreting test 
results (88).  
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3.1.3 Microdialysis monitoring of the kidney (Paper I) 
In the renal study the microdialysis probes are introduced into the renal cortex and medulla 
using introduction needles. At the time the study was performed microdialysis monitoring of 
the kidney had not been previously studied to any extent. However, since then several studies 
have demonstrated microdialysis to be a safe and reproducible method for studying renal 
metabolism in the transplantation setting in clinical and experimental models (95-98).  
3.1.4 Microdialysis monitoring of the liver (Paper II, III, IV and V) 
For intrahepatic microdialysis monitoring, a microdialysis catheter is placed in liver segment 
IV at the end of surgery, before closure of the abdomen. It can be sutured to the falciform 
ligament for stability and the pump is fixed to the abdominal wall using dressings (Figure 8). 
Previous studies have shown the microdialysis monitoring technique to be safe and easy to 
perform in liver transplantation in the experimental and clinical setting (76, 99). In a clinical 
study by Håugaa et al., on microdialysis after liver transplantation, performed around the time 
of the studies described in this thesis, suggested cut-off values of lactate and L/Pr for 
detection of ischemic complications were presented (100).  
 
              
Figure 8. Microdialysis probe placement in the liver and fixation (to the left) with dressings 
following abdominal closure (to the right) 
3.2 EXPERIMENTAL STUDIES (PAPER I,II AND V) 
All procedures were conducted in strict accordance with the criteria of the Ethics Committee 
for Animal Experiments at Karolinska Institutet. A porcine model was used for its similarity 
to the clinical setting with regards to solid organ transplantation (Paper I, II and V). Cross-
bred (Swedish Landrace/Yorkshire/Hampshire) female pigs were used. Before operation, 
animals were fasted with free access to water for up to 36 hours. Anaesthesia was induced 
with intramuscular premedication of 12mg/kg ketamine hydrochloride, 5mg/kg azaperone 
and 0.05mg/kg atropine. 1-4mg/kg Midazolam was given prior to intubation. Anaesthesia 
was maintained by inhalation of a mixture of oxygen, nitric oxide and halothane. Invasive 
blood pressure, electrocardiogram, urine production, body temperature and blood gas analysis 
(study V), was monitored throughout the experiment. Body temperature was kept between 
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38-39oC using an external heating device. Animals were kept on continuous infusion of 
Ringer acetate solution at a volume of 6-8 ml/kg. At the end of the experiment animals were 
sacrificed under deep anaesthesia by intravenous injection of over-dose pentobarbital.  
3.3 CLINICAL STUDIES (PAPER III AND IV) 
Patients undergoing liver transplantation at the Karolinska University Hospital were included. 
Liver transplantation was performed with preservation of the recipient vena cava inferior 
using the piggyback technique as standard (Figure 3). Venovenous bypass was used in 
selected cases. Basic immunosuppression was achieved with steroids and Tacrolimus. High 
molecular weight Dextran was used post transplantation for thrombosis prophylaxis followed 
by acetylsalicylic acid. Throughout post-operative intensive care stay, blood glucose was 
measured every hour by arterial blood gas. During post-operative days 1 and 2, patients were 
administered 5% glucose infusions at 30 ml/kg/day. On the third postoperative day, patients 
were given half a dose of total parenteral nutrition (25 kcal/kg/day). Thereafter full dose of 
parenteral nutrition was given and patients were allowed to eat. Target blood glucose value 
was < 8 mmol/L. 
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3.4 METHODOLOGICAL OVERVIEW 
 
 Population Methods 
Paper I 8 cross-bred (Swedish 
Landrace/Yorkshire/Hampshire) 
littermate female pigs, 28-34 kg 
Prospective study. Intra-renal microdialysis 
followed by pneumoperitoneum. 
Retrospective analysis of microdialysis data. 
Paper II 26 cross-bred (Swedish 
Landrace/Yorkshire/Hampshire) 
female pigs, 30-34 kg 
Prospective study. Group I (n = 6) liver 
transplantation with CI of 5h. Group II (n = 
7) liver transplantation with CI of 15h. 
Intrahepatic microdialysis. Retrospective 
analysis of microdialysis data. 
Paper III 45 patients undergoing liver 
transplantation at Karolinska 
University Hospital Huddinge 
Prospective study. Intrahepatic and 
subcutaneous microdialysis up to 6 days 
post-op. Bedside and retrospective analysis 
of medical and microdialysis data.  
Paper IV 71 patients undergoing liver 
transplantation at Karolinska 
University Hospital Huddinge 
Prospective study. Intrahepatic and 
subcutaneous microdialysis up to 6 days 
post-op. Retrospective analysis of medical 
and microdialysis data. 
Paper V 8 cross-bred (Swedish 
Landrace/Yorkshire/Hampshire) 
female pigs, 30-35 kg. 
Prospective study. Intrahepatic, subcutaneous 
and intravenous (middle hepatic vein) 
microdialysis. Induction of ischemia by 
clamping of hepatic artery. Retrospective 
analysis of microdialysis data. 
 
Table 1. Patients, experimental models and methods used in the studies 
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In Paper I Eight cross-bred littermate female pigs were used in the study. Under anaesthesia 
and following laparotomy, microdialysis catheters (CMA 70) with a 60 mm shaft (diameter 
0.9mm) and a 30-mm membrane (20 kDa cut-off) were inserted in the cortex and the medulla 
of the left kidney. Samples were collected at 30-min intervals and analysed with respect to 
glucose, lactate, pyruvate and glycerol. The L/Pr was calculated. Following placement of the 
catheters the abdomen was closed and pneumoperitoneum was induced by intraperitoneal 
insufflation of carbon dioxide via a standard laparoscopic port. Intraabdominal pressure was 
kept at 16 to 18 mmHg for a duration of 4 h. After 4 h, desufflation was performed and the 
kidney was monitored for another 2 hours. Microdialysis data was analysed for differences 
during and after insufflation as well as differences between cortex- and medullar placement. 
In Paper II 26 cross-bred female pigs were used for 13 orthotopic liver transplantations. 
Animals were divided into 2 groups: group I (n = 6) with liver graft exposed to 4 h of CI and 
group II (n = 7) with liver grafts exposed to 14 h of CI. In both groups cold ischemia was 
followed by 1 h of rewarming ischemia after which time the liver was reperfused. Liver grafts 
were perfused with 4oC University of Wisconsin (UW) solution via the portal vein and 
hepatic artery following hepatectomy. They were then statically stored in UW solution on ice 
throughout the cold ischemia period. Following abdominal incision microdialysis catheters 
(described above) were inserted into the liver and subcutaneous tissue which was used for 
reference. Microdialysis samples were collected at 20-minute intervals throughout the 
experiment and analysed as described for paper I. Liver graft monitoring was continued 2 
hours after reperfusion was achieved. Microdialysis data was compared between the groups. 
In Paper III 45 patients undergoing liver transplantation were included in the study. Familial 
amyloidotic polyneuropathy was the most common indication for transplantation (20%) 
followed by HCV (18%), hepatocellular carcinoma (16%) and primary sclerosing cholangitis 
(11%). Liver transplantation was carried out using piggyback technique as the standard. At 
the end of the operation microdialysis catheters were placed in the liver graft and in 
subcutaneous tissue for reference. Microdialysis samples were collected once every hour up 
for up to 6 days post-operatively and analysed as previously described. Suspicion of ischemic 
complications were investigated by contrast enhanced ultrasound of the liver and CT 
angiography scan. An ischemic complication was defined as vascular occlusion or infarction 
confirmed by radiology. Based on our previous studies episodes with increasing L/Pr in three 
consecutive samples and an increase of at least 30% in total, were regarded as related to 
tissue ischemia (76, 101). Also suggested cut-off values were used (100). Microdialysis data 
was compared to clinical data.  
In Paper IV 71 patients undergoing liver transplantation were included in the study. 
Hepatocellular carcinoma was the most common indication for transplantation (18%), 
followed by primary sclerosing cholangitis (15%), familial amyloidotic polyneuropathy 
(14%) and HCV (14%). At the end of liver transplantation microdialysis catheters were 
placed in the liver and in subcutaneous tissue for reference. Samples were collected every 
hour and analysed as previously described. Time-zero biopsies were taken and graded for 
  19 
IRI. Rejection was classified according to RAI (37). Microdialysis data was compared for 
groups with and without rejection. 
In Paper V Eight cross-bred littermate female pigs were used in the experiment. Following 
laparotomy, microdialysis catheters were placed in the liver and in subcutaneous tissue for 
reference. A third catheter was placed in the middle hepatic vein by introduction through the 
internal jugular vein. Flow rate was 0.3l/min in the intrahepatic and reference catheters and 
1l/min in the intravenous catheter. Following a period of equilibration the hepatic artery was 
clamped for four hours to induce ischemia. Microdialysis samples were collected at 15-
minute intervals from the intrahepatic and intravenous catheters and at 30-minute intervals 
from the reference catheter. Microdialysis data from the three different catheters was 
compared.  
3.5 ETHICAL CONSIDERATIONS 
Experimental studies were approved by the Ethics Committee for Animal Experiments at the 
Karolinska Institute. Clinical studies were approved by the Ethics Committee for Clinical 
Studies at the Karolinska Institute in accordance with guidelines of the Helsinki Declaration. 
Written and oral consent was obtained from all patients included in the clinical studies.  
3.6 STATISTICAL METHODS 
ANOVA test for repeated measurements was used in paper II, VI and V for analysing 
differences between groups. Mann-Whitney U-test was applied in paper II and IV for 
analysing differences between groups. Area under the curve (AUC) was calculated for entire 
time points and analysed using a two-tailed t-test for dependent samples in paper I, II and 
IV. To analyse the difference between values during pneumoperitoneum and after 
desufflation nonparametric Wilcoxon’s matched-pairs tests was used in paper I. Bonferroni 
post-hoc test was used to analyse differences between groups over time in paper V. For 
paper III descriptive statistics were applied. Differences were considered significant in tests 
with a p-value less than 0.05. 
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4 RESULTS 
 
 Main findings 
Study I There was a significant increase in glycerol in the renal medulla after 
desufflation. 
Study II An increase in intrahepatic glucose following portal reperfusion was seen in 
both groups and was significantly higher in the group with longer CI time.  
An increase in L/Pr was seen in both groups during rewarming ischemia. This 
increase was significantly higher and persisted 20 min after portal reperfusion 
in the group with long CI. 
Study III There was no correlation between episodes of increased L/P r and ischemic 
events after transplantation.  
Study IV A significant increase in L/Pr during the initial 12 hours post-transplant was 
correlated to development of post-transplant rejection .  
Study V There were no changes in glucose, lactate, pyruvate or L/Pr measured i.v. in the 
hepatic vein during or after clamping of the hepatic artery. 
 
Paper I 
Glucose remained stable in both renal cortex and medulla throughout the experiment. Lactate 
levels showed a tendency to decrease in the cortex and medulla after induction of 
pneumoperitoneum. Following decompensation, lactate levels increased and showed a 
plateau. There were no significant changes in pyruvate or L/Pr levels in the cortex or medulla 
throughout the experiment. Glycerol levels were stable in the cortex and medulla during 
pneumoperitoneum (Figure 9). Following desufflation, there was a significant increase in 
glycerol in the medulla which was persistent over time. Glycerol levels remained stable in the 
cortex.  
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Figure 9. Glycerol concentrations in the renal cortex and medulla. There was no change 
before (area 1) or during (area 2 and 3) pneumoperitoneum in the cortex or the medulla. 
After decompensation (area 4), tissue glycerol in the medulla increased. Paper I 
 
 
Paper II 
 
Significantly higher levels of glucose were observed after portal reperfusion in livers exposed 
to a longer CI time. Also, in this group peak levels were reached with a delay compared to 
livers with short CI time (Figure 10).  
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Figure 10. Intrahepatic levels of glucose at the time of: (I) before donation, (II) the end of 
cold ischemia, (III) portal reperfusion, (VI) peak levels after portal reperfusion, and (V) 2 h 
after portal reperfusion: in transplanted liver grafts with short (4h) and long (14h) periods of 
cold ischemia (CI). Paper II 
 
Monitored increases in glucose observed in both groups correspond to a decrease in glycogen 
in histological exam using Periodic acid Schiff (PAS) staining (Figure 11). 
 
 
Figure 11. Intrahepatic glucose levels measured with microdialysis and glycogen storage in 
liver biopsy (amount of glycogen corresponding to the intensity of the color in 
histopathological staining (PAS)).  
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Lactate levels remained stable in both groups after cold perfusion and during CI. During WI, 
lactate levels increased in both groups (up to 4.0  1.6mM and 5.1  1.2mM, respectively). 
The increase continued after portal reperfusion and reached peak levels of 9.9  1.8mM and 
11.7  2.6mM respectively. Thereafter lactate levels decreased. No difference between 
groups was observed despite significant changes over time. Pyruvate decreased rapidly 
following cold perfusion in both groups (from 163.1  93.8M to 14.9  7.6M in the short 
CI group and from 179.4  56.0M to < 10M in the long CI group). An increase in pyruvate 
was observed after portal reperfusion in both groups. Despite significant changes in pyruvate 
levels over time, there was no difference between the groups. L/Pr increased in both groups 
during CI (Figure 12). Following this increase a stabilization was seen. During WI L/Pr 
increased further in both groups. After portal reperfusion L/Pr continued to increase in livers 
with long CI whereas a rapid decrease was seen in the group with short CI. This difference 
between groups was significant (p < 0.01).  
 
  
Figure 12. Intrahepatic L/Pr at the time of: (I) before donation, (II) the end of cold ischemia, 
(III) portal reperfusion, (IV) peak levels after portal reperfusion and (V) 2h after portal 
reperfusion in transplanted liver grafts with short (4h) and long (14 h) periods of cold 
ischemia. Paper II 
 
Paper III 
No adverse events related to the microdialysis monitoring were observed in the patient 
cohort. One patient developed HAT. Two patients were of particular interest and are 
described below: 
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Patient 1 
A 22-year old male with cryptogenic liver cirrhosis underwent liver transplantation with a 
split liver from a deceased donor. The initial post-operative period was uneventful. One week 
after liver transplantation bilirubin increased and the patient was diagnosed with HAT 
following radiological investigation. Retrospective analysis of the microdialysis data showed 
that at 22 hours (Figure 13). Arterial thrombosis was expected to result in a higher and 
prolonged increase in L/Pr and therefore, unfortunately, the observed changes did not lead to 
any further investigation at the time.  
 
 
 
Figure 13. Intrahepatic L/Pr and subcutaneous glucose measured by microdialysis, over time 
after liver transplantation in patient 1. Paper III 
 
Patient 2 
A 55-year old male underwent liver transplantation due to HCV cirrhosis. Initial post-
operative recovery was uneventful. Sixty-five hours after liver transplantation L/Pr increased 
by 50% over a period of three hours (Figure 14). The patient was investigated under 
suspicion of HAT but was found to have normal arterial and portal circulation.  
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Figure 14. Intrahepatic L/Pr and subcutaneous glucose measured by microdialysis over time 
after liver transplantation in patient 2. Paper III 
 
Overall results 
Forty-four events of increased L/Pr (defined in the study protocol) were identified in 22 
patients (Table 2). Eight patients had simultaneous L/Pr and lactate values above cut-off 
values suggested by Håugaa et al (100). None of these 22 or eight patients experienced 
ischemic events. Detailed analysis of the events of increased L/Pr was done to study lactate 
and pyruvate levels at the time of L/Pr increase (Table 3). Only 18% of events of increased 
L/Pr was the result of increase in lactate and decrease in pyruvate, changes which might 
indicate ischemia.  
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Table 2. Metabolic events and ischemic complications. Paper III 
 
Table 3. Detailed analysis of events of increased L/Pr in liver transplanted patients 
Paper IV 
Of the 71 patients included in the study, 33 (46%) developed ACR within the first month 
after liver transplantation. The microdialysis catheter was removed to increase mobility for 
most patients on day 3 following liver transplantation. For this, only the first 72 hours of data 
are presented. The L/Pr was higher in the rejection group at 1-12 hours after liver 
transplantation (Figure 15). In the group without rejection glucose was higher at 24-48 hours. 
Intrahepatic lactate levels were higher at 48-72 hours and pyruvate levels were higher at 60-
72 hours after liver transplantation in the group with rejection as compared to non-rejectors. 
There was no significant difference in glycerol levels between groups. Forward stepwise 
logistic regression analysis showed L/Pr at 1-12 hours after transplantation to be the only 
independent predictor of early post-transplant rejection (p = 0.05).  
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Figure 15. L/Pr in the liver after transplantation. Data presented as mean  95% confidence 
intervals. Paper IV 
 
Paper V 
There were no complications associated with the insertion or removal of the microdialysis 
catheters. In the intrahepatic catheter a significant increase in lactate and decrease in pyruvate 
levels was seen during clamping of the hepatic artery. However, the resulting increase in L/Pr 
was not significant. In the subcutaneous catheter both lactate and pyruvate levels increased 
during clamping. There were no significant changes in glycerol in any of the catheters. The 
catheter placed in in the hepatic vein showed no significant changes for any of the measured 
metabolites throughout the experiment. This indicates that intravenous microdialysis 
sampling in the hepatic vein cannot mimic the metabolic changes seen in intraheptatic 
microdialysis.  
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5 GENERAL DISCUSSION 
 
5.1  ISCHEMIA AND ISCHEMIC COMPLICATIONS 
The liver plays a central metabolic role in the human body. When exposed to ischemic 
conditions during the transplantation process, significant changes in liver metabolism occur. 
As shown in paper II, glucose levels in the liver remain stable throughout cold ischemia. 
Also, despite obvious ischemic conditions, lactate levels are low and stable in the same 
period. This indicates that glucose metabolism is effectively suppressed during cold ischemia. 
During warm ischemia glucose levels start to increase. Histopathological evaluation of the 
liver grafts prior to transplantation showed normal glycogen storage. The same examination 
performed at the time of reperfusion showed depleted glycogen storage in both groups, 
suggesting that the glucose increase in liver tissue seen during warm ischemia is the result of 
glycogenolysis. Following portal and arterial reperfusion, glucose released from the liver 
during warm ischemia, is flushed into the systemic circulation and results in post-reperfusion 
hyperglycemia (102, 103). The lactate/pyruvate ratio which is frequently used as an indicator 
of ischemia, was seen to decrease after reperfusion as expected. Interestingly, in the group 
with liver grafts exposed to longer cold ischemia, the decrease in lactate/pyruvate ratio 
occurred later than in the group with short cold ischemia, indicating a delay in the recovery of 
aerobic metabolism despite restoration of aerobic conditions. Detailed analysis shows that the 
increase in lactate/pyruvate ratio during this time is a result of delayed pyruvate production, 
rather than an increase in lactate production. Thus, the prolonged effect of ischemia seems to 
be related to a delayed start of glucose utilization rather the rate of nonoxidative glycolysis. 
Our results suggest that glycolysis does not take place during cold ischemia. However, an 
injury to the mechanism controlling glycolysis, most likely enzymes, seems to take place 
during this time and the degree of metabolic dysfunction seems to increase significantly with 
the length of cold ischemia.  
Similar metabolic changes can be expected to be seen during ischemic insult to the 
transplanted liver caused by hepatic artery thrombosis or portal vein thrombosis. A previous 
study by our group confirms this in the experimental setting (101). Vascular complications 
following liver transplantation though relatively rare, are life- and graft threatening. Methods 
for detection should therefore ideally have a high sensitivity. In paper III, only 1 patient 
(2%) suffered from hepatic artery thrombosis which makes drawing statistically valid 
conclusions regarding metabolic patterns during ischemia difficult. However, this patient did 
not experience an increase in lactate/pyruvate ratio high enough to indicate ischemia as 
defined by the study protocol. Nor was the increase in lactate and lactate/pyruvate ratio high 
enough to reach the cutoff values suggested by Håugaa et al (100). Furthermore, analysis of 
the microdialysis data from the study cohort identified 44 events of increased lactate/pyruvate 
ratio suggesting hepatic ischemia in 24 patients, none of whom suffered vascular 
complications. Detailed analysis of the events of increased lactate/pyruvat showed that 59% 
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of cases occur during decreasing levels of lactate and pyruvate, with pyruvate decreasing at a 
faster rate. A decrease in metabolites suggest metabolic recovery rather than ischemia.  
It is not fully understood how the metabolic pathways involving glucose are affected or 
injured by the ischemia which the transplantation process entails (104). While microdialysis 
is useful for detecting primary metabolic changes, the lactate/pyruvate ratio is not a reliable 
or specific marker for secondary events such as ischemic complications, early after liver 
transplantation.  
5.2 REJECTION 
When using microdialysis, the recovery rate of metabolites is highly dependent on previously 
mentioned factors and absolute values of metabolite concentrations should not be used for 
interpretation. Instead relative changes over time more accurately reflect changes in 
metabolite concentration in the tissue. As acute cellular rejection is not an instantaneous event 
like a vascular complication, evaluating trends over time is a more appropriate approach for 
studying rejection. Results from paper IV show that intrahepatic lactate/pyruvate ratio at 0-
12 h after transplantation is higher in patients who later develop rejection. Also, the 
lactate/pyruvate ratio was the only parameter associated with rejection during this time. The 
difference in lactate/pyruvate ratio between the groups in the early post-transplant period is a 
likely result of differences in the degree of perioperative ischemia-reperfusion injury which 
has previously been linked to the development of acute cellular rejection (52, 105, 106). 
However, this correlation was not seen in the zero-time biopsy or in other donor related 
parameters.  
Patients who went on to develop acute cellular rejection had higher intrahepatic lactate and 
pyruvate levels day 3 after transplantation than patients who did not. This could be the result 
of post-ischemic hypermetabolism which has been shown to occur as a response to ischemia 
in other tissues (107, 108). The results form paper IV indicate that microdialysis monitoring 
following liver transplantation may be useful in the detection of metabolic events that precede 
acute cellular rejection. As such, microdialysis may be helpful in selecting patients who 
would benefit from higher levels of immunosuppression within the recommended 
concentration ranges However, it is questionable whether microdialysis can detect rejection 
by itself. The observed association between ischemia-reperfusion injury and development of 
acute cellular rejection stresses the importance of reducing the duration and severity of 
ischemia and limiting the effects of ischemia-reperfusion injury after liver transplantation.  
5.3 TISSUE DAMAGE 
Cellular membrane disintegration causes a release of glycerol which is used as an indicator of 
cellular damage (109). In paper I an increase in glycerol levels is seen in the renal medulla 
following release of pneumoperitoneum. Glucose levels, reflecting blood flow, and the 
parameters of anaerobic metabolism including the lactate/pyruvate ratio, remain unchanged 
throughout the experiment. This indicates that pneumoperitoneum does not induce reduced 
blood flow or oxygen supply to the kidney. The observed increase in glycerol levels in the 
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renal medulla is most likely related to some type of cell membrane injury which does not 
seem to be related to ischemia. Laparoscopic procedures may cause ischemia-reperfusion-like 
injury to the abdominal organs and tissues with release of free radicals during a reperfusion 
period (110, 111). Possibly, rapidly increasing glycerol levels in the renal medulla after 
desufflation may reflect cell damage due to this phenomenon. Tissue biopsies were not taken 
as previous studies have shown there to be no histological difference between kidneys 
harvested by open versus laparoscopic technique (112, 113).  
Rejection is expected to result in an increase in glycerol levels due to the break-down of 
cellular membranes mediated by T-cells during rejection. Most likely, the microdialysis 
monitoring time in paper IV was too short for any changes in glycerol levels to be detected 
as only 3 patients remained with monitoring between day 5 and 6. This highlights a problem 
of long-term monitoring as many patients chose to have the catheter removed for improved 
mobility and comfort.  
The ischemia-related tissue damage caused by clamping of the hepatic artery in pigs in paper 
V could also be expected to result in increase in glycerol levels. Although such an increase 
was seen in several of the individuals in our study, the increase was not significant due to a 
high level of variation between individuals.  
5.4 METHODOLOGICAL CONSIDERATIONS   
Microdialysis has proven to be a promising tool for continuous monitoring of tissue 
metabolism and pharmacological studies. However, despite encouraging results from animal 
experiments and a wide range of clinical studies over the past two decades, microdialysis has 
not gained a foothold in standard clinical practice. Several factors contribute to difficulties 
with applicability of the microdialysis technique in the surgical field and especially in 
transplantation. Despite the large number of studies on microdialysis in surgical settings no 
consensus has been established on reference values for normal versus complicated outcomes. 
Glucose, lactate, pyruvate and glycerol are metabolites which in theory may be correlated to 
ischemia and cellular damage. However, the metabolic pathways at play during inflammation 
and ischemia are highly complex and not fully understood. For example as shown in paper 
III, increase in lactate/pyruvate ratio does not exclusively result from increase in lactate and 
decrease in pyruvate. As such it does not solely describe the balance between aerobic and 
anaerobic metabolism. It seems that microdialysis is useful for detection of primary metabolic 
changes. However, a better understanding of the recovery of metabolic processes after 
ischemia-reperfusion injury is needed to enable the use of microdialysis for monitoring of 
secondary events following ischemia-reperfusion injury and liver transplantation using more 
specific biomarkers.  
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6 CONCLUSIONS 
 
Microdialysis seems to be a safe and useful tool for detection of metabolic changes in tissues 
such as kidney and the transplanted liver. However, interpretation of these changes is difficult 
in tissue exposed to ischemia-reperfusion injury since the recovery of the metabolic processes 
involved is not fully understood.  
1. Pneumoperitoneum induces increased glycerol levels in renal medulla after 
desufflation. This is likely the result of cell damage caused by reperfusion-like injury 
in the medulla. 
 
2. In liver tissue exposed to cold ischemia, glycolysis does not take place. However, 
during this time, an injury to the mechanisms controlling glycolysis likely takes place 
resultning in a slower start in glucose utilisation in liver tissue exposed to longer cold 
ischemia time.  
 
3. The lactate/pyruvate ratio is a product of the complex interplay of changes in liver 
metabolism which makes interpretation of changes in intrahepatic lactate/pyruvate 
ratio early after liver transplantation difficult. The lactate/pyryvate ratio is thus a poor 
marker of clinically relevant ischemia in the liver early after transplantation. 
 
4. Microdialysis monitoring following liver transplantation may be useful for detection 
of metabolic events that preced acute cellular rejection. However, it is questionable 
whether it can detect rejection by itself. The metabolic changes seen in patients who 
go on to develop acute cellular rejection are possibly linked to ischemia-reperfusion 
injury during transplantation. Finding ways to reduce the duration of ischemia and the 
effects of ischemia-reperfusion injury after liver transplantation would be beneficial. 
 
5. Hepatic vein microdialysis could not be used to represent direct intrahepatic 
microdialysis for detection of metabolic changes induced by hepatic arterial ischemia 
in the study presented in this thesis. 
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